American Bio Medica Corporation
ABMC · OTC
3/31/2023 | 12/31/2022 | 9/30/2022 | 6/30/2022 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -1.8% | -20.1% | 13% | – |
| Gross Profit | $0 | -$0 | -$0 | -$0 |
| % Margin | 45.1% | -83.8% | -4.3% | -39.5% |
| EBITDA | $0 | -$0 | -$0 | -$0 |
| % Margin | 1,164.6% | -157.5% | -119.1% | -180% |
| Net Income | $0 | -$0 | -$0 | -$0 |
| % Margin | 2,410.4% | -189.8% | -175.1% | -216.2% |
| EPS Diluted | 0.082 | -0.007 | -0.008 | -0.008 |
| % Growth | 1,345.5% | 13.2% | 8.4% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |